CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Hold” by Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average rating of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $6.42.

CTMX has been the subject of several recent research reports. Wedbush raised CytomX Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $3.00 to $8.00 in a report on Thursday. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Thursday. Jefferies Financial Group raised CytomX Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $2.50 to $8.00 in a report on Monday. BMO Capital Markets raised their target price on CytomX Therapeutics from $3.25 to $3.59 and gave the company a “market perform” rating in a report on Thursday. Finally, StockNews.com downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd.

CytomX Therapeutics Stock Down 42.7 %

Shares of NASDAQ CTMX traded down $1.79 during mid-day trading on Thursday, hitting $2.40. 23,087,179 shares of the company were exchanged, compared to its average volume of 4,144,598. The stock has a 50 day simple moving average of $2.38 and a 200-day simple moving average of $1.78. CytomX Therapeutics has a 1-year low of $1.04 and a 1-year high of $5.85. The firm has a market cap of $163.53 million, a price-to-earnings ratio of -117.50 and a beta of 1.09.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to analysts’ expectations of $23.36 million. Analysts anticipate that CytomX Therapeutics will post -0.25 earnings per share for the current fiscal year.

Insider Activity at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.09, for a total transaction of $42,266.07. Following the completion of the sale, the chief executive officer now directly owns 524,481 shares in the company, valued at $1,096,165.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 35,024 shares of company stock valued at $73,200. 7.00% of the stock is owned by insiders.

Institutional Trading of CytomX Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. Bank of New York Mellon Corp boosted its holdings in shares of CytomX Therapeutics by 737.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock valued at $344,000 after purchasing an additional 234,970 shares during the last quarter. Congress Park Capital LLC lifted its stake in shares of CytomX Therapeutics by 112.8% in the 4th quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 126,850 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of CytomX Therapeutics in the 1st quarter valued at about $124,000. SG Americas Securities LLC acquired a new position in shares of CytomX Therapeutics in the 1st quarter valued at about $57,000. Finally, AlphaMark Advisors LLC lifted its stake in shares of CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 12,635 shares in the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.